Annual CFF
$3.97 M
-$7.62 M-65.72%
December 31, 2023
Summary
- As of February 7, 2025, AQST annual cash flow from financing activities is $3.97 million, with the most recent change of -$7.62 million (-65.72%) on December 31, 2023.
- During the last 3 years, AQST annual CFF has fallen by -$24.48 million (-86.04%).
- AQST annual CFF is now -93.15% below its all-time high of $58.03 million, reached on December 31, 2018.
Performance
AQST Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
-$17.00 K
-$1.73 M-100.99%
September 30, 2024
Summary
- As of February 7, 2025, AQST quarterly cash flow from financing activities is -$17.00 thousand, with the most recent change of -$1.73 million (-100.99%) on September 30, 2024.
- Over the past year, AQST quarterly CFF has dropped by -$5.00 million (-100.34%).
- AQST quarterly CFF is now -100.02% below its all-time high of $81.74 million, reached on March 31, 2024.
Performance
AQST Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$87.35 M
-$5.00 M-5.41%
September 30, 2024
Summary
- As of February 7, 2025, AQST TTM cash flow from financing activities is $87.35 million, with the most recent change of -$5.00 million (-5.41%) on September 30, 2024.
- Over the past year, AQST TTM CFF has increased by +$87.05 million (+29509.49%).
- AQST TTM CFF is now -7.98% below its all-time high of $94.92 million, reached on March 31, 2024.
Performance
AQST TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
AQST Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -65.7% | -100.3% | +10000.0% |
| 3 y3 years | -86.0% | -100.3% | +10000.0% |
| 5 y5 years | -93.2% | -100.3% | +10000.0% |
AQST Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -86.8% | at low | -100.0% | +99.8% | -8.0% | +1911.5% |
| 5 y | 5-year | -92.0% | at low | -100.0% | +99.8% | -8.0% | +1911.5% |
| alltime | all time | -93.2% | at low | -100.0% | +99.8% | -8.0% | +1225.9% |
Aquestive Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$17.00 K(-101.0%) | $87.35 M(-5.4%) |
| Jun 2024 | - | $1.71 M(-97.9%) | $92.34 M(-2.7%) |
| Mar 2024 | - | $81.74 M(+1989.0%) | $94.92 M(+2288.5%) |
| Dec 2023 | $3.97 M(-65.7%) | $3.91 M(-21.4%) | $3.97 M(+1247.1%) |
| Sep 2023 | - | $4.98 M(+16.1%) | $295.00 K(-106.1%) |
| Jun 2023 | - | $4.29 M(-146.6%) | -$4.82 M(-542.8%) |
| Mar 2023 | - | -$9.21 M(-4033.8%) | $1.09 M(-90.6%) |
| Dec 2022 | $11.59 M(-61.5%) | $234.00 K(-269.6%) | $11.59 M(-31.0%) |
| Sep 2022 | - | -$138.00 K(-101.4%) | $16.81 M(-27.0%) |
| Jun 2022 | - | $10.20 M(+685.7%) | $23.03 M(+7.0%) |
| Mar 2022 | - | $1.30 M(-76.2%) | $21.52 M(-28.5%) |
| Dec 2021 | $30.11 M(+5.8%) | $5.45 M(-10.3%) | $30.11 M(-43.3%) |
| Sep 2021 | - | $6.08 M(-30.0%) | $53.15 M(+12.9%) |
| Jun 2021 | - | $8.69 M(-12.2%) | $47.06 M(+22.6%) |
| Mar 2021 | - | $9.89 M(-65.3%) | $38.38 M(+34.9%) |
| Dec 2020 | $28.46 M | $28.49 M(<-9900.0%) | $28.46 M(-27.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2020 | - | -$7000.00(-170.0%) | $39.04 M(-25.9%) |
| Jun 2020 | - | $10.00 K(-127.0%) | $52.67 M(+1.0%) |
| Mar 2020 | - | -$37.00 K(-100.1%) | $52.17 M(+5.2%) |
| Dec 2019 | $49.60 M(-14.5%) | $39.07 M(+186.7%) | $49.60 M(+374.8%) |
| Sep 2019 | - | $13.63 M(-2864.5%) | $10.45 M(-83.2%) |
| Jun 2019 | - | -$493.00 K(-81.1%) | $62.08 M(+9.2%) |
| Mar 2019 | - | -$2.61 M(+3121.0%) | $56.84 M(-2.1%) |
| Dec 2018 | $58.03 M(+1214.8%) | -$81.00 K(-100.1%) | $58.03 M(+0.8%) |
| Sep 2018 | - | $65.27 M(-1238.2%) | $57.55 M(-841.8%) |
| Jun 2018 | - | -$5.73 M(+304.7%) | -$7.76 M(+282.7%) |
| Mar 2018 | - | -$1.42 M(+149.9%) | -$2.03 M(-145.9%) |
| Dec 2017 | $4.41 M(-22.4%) | -$567.00 K(+1317.5%) | $4.41 M(-11.4%) |
| Sep 2017 | - | -$40.00 K(+1233.3%) | $4.98 M(-0.8%) |
| Jun 2017 | - | -$3000.00(-100.1%) | $5.02 M(-0.1%) |
| Mar 2017 | - | $5.02 M | $5.02 M |
| Dec 2016 | $5.69 M | - | - |
FAQ
- What is Aquestive Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Aquestive Therapeutics?
- What is Aquestive Therapeutics annual CFF year-on-year change?
- What is Aquestive Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Aquestive Therapeutics?
- What is Aquestive Therapeutics quarterly CFF year-on-year change?
- What is Aquestive Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Aquestive Therapeutics?
- What is Aquestive Therapeutics TTM CFF year-on-year change?
What is Aquestive Therapeutics annual cash flow from financing activities?
The current annual CFF of AQST is $3.97 M
What is the all time high annual CFF for Aquestive Therapeutics?
Aquestive Therapeutics all-time high annual cash flow from financing activities is $58.03 M
What is Aquestive Therapeutics annual CFF year-on-year change?
Over the past year, AQST annual cash flow from financing activities has changed by -$7.62 M (-65.72%)
What is Aquestive Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of AQST is -$17.00 K
What is the all time high quarterly CFF for Aquestive Therapeutics?
Aquestive Therapeutics all-time high quarterly cash flow from financing activities is $81.74 M
What is Aquestive Therapeutics quarterly CFF year-on-year change?
Over the past year, AQST quarterly cash flow from financing activities has changed by -$5.00 M (-100.34%)
What is Aquestive Therapeutics TTM cash flow from financing activities?
The current TTM CFF of AQST is $87.35 M
What is the all time high TTM CFF for Aquestive Therapeutics?
Aquestive Therapeutics all-time high TTM cash flow from financing activities is $94.92 M
What is Aquestive Therapeutics TTM CFF year-on-year change?
Over the past year, AQST TTM cash flow from financing activities has changed by +$87.05 M (+29509.49%)